Cellular therapies using regulatory T (Treg) cells are currently undergoing clinical trials for
the treatment of autoimmune diseases, transplant rejection and graft-versus-host disease. In …

For decades, it was commonly accepted that the brain is secluded from peripheral immune
activity and is self-sufficient for its maintenance and repair. This simplistic perception was …

Background Alzheimer's disease (AD) is a progressive neurodegenerative disorder
characterized by pathological deposition of misfolded self-protein amyloid beta (Aβ) which in …

Recent evidence suggests the commensal microbiome regulates host immunity and
influences brain function; findings that have ramifications for neurodegenerative diseases. In …

Alzheimer's disease (AD) represents an urgent public health mandate. AD is no longer
considered a neural-centric disease; rather, a plethora of recent studies strongly implicate a …

Immunomodulation holds therapeutic promise against brain injuries, but leveraging this
approach requires a precise understanding of mechanisms. We report that CD8+ CD122+ …

Neurodegenerative diseases of the central nervous system (CNS) are characterized by
progressive neuronal death and neurological dysfunction, leading to increased disability …

Alzheimer disease (AD) is the most common neurodegenerative disease, and with no
efficient curative treatment available, its medical, social, and economic burdens are …

Regulatory T cells (Tregs) control inflammation and maintain immune homeostasis. The well-
characterised circulatory population of CD4+ Foxp3+ Tregs is effective at preventing …

T cells, the critical immune cells of the adaptive immune system, are often dysfunctional in
Alzheimer's disease (AD) and are involved in AD pathology. Reports highlight …